logo
QuantumScape: 40x Upside For QS Stock?

QuantumScape: 40x Upside For QS Stock?

Forbes3 days ago

GERMANY - 2024/12/20: In this photo illustration, a person is holding a smartphone with the logo of ... More US battery company QuantumScape Corporation on screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)
QuantumScape stock surged 75% this week following the company's announcement of a breakthrough in manufacturing. The recent advancement with the Cobra separator signifies more than just a manufacturing achievement—it positions the company as a leader in a vast market opportunity. This innovative process achieves heat treatment speeds that are 25 times faster while occupying significantly less space, addressing crucial scalability issues that have long impeded the commercialization of solid-state batteries. For more details, see our previous analysis on – QuantumScape: What's Happening With QS Stock?. This note focuses on the potential for QS stock to appreciate. However, if you're seeking an upside with a smoother experience than picking an individual stock, you might want to consider the High Quality Portfolio, which has outperformed the S&P and achieved returns greater than 91% since inception. Also, check out – BigBear.ai: What's Happening With BBAI Stock?
The Market Opportunity
The timing of QuantumScape's technological advancement coincides with remarkable growth in the U.S. electric vehicle market. BloombergNEF forecasts that U.S. passenger EV sales will grow from 1.6 million in 2024 to 4.1 million by 2030, indicating a compound annual growth rate exceeding 17%.
Capturing just 25% of this target market by 2030 would equate to around 1 million vehicles sold annually. With an estimated $10,000 per battery pack, this translates to a $10 billion revenue potential for QuantumScape.
The figures become even more enticing when considered through the lens of production capacity. QuantumScape is projecting a production capacity of 90 GWh in the years to come. Based on industry estimates of $120 per kWh, this capacity could yield approximately $11 billion in gross revenue.
Valuation Disconnect
The current market capitalization of QuantumScape is approximately $4 billion, presenting a notable valuation opportunity. The company is trading at merely 0.4 times its potential revenues for 2030—a significant discount for a technology leader poised to grow from nothing to over $10 billion in revenue within a few years.
High-growth technology firms usually command revenue multiples ranging from 15 to 30 times during periods of rapid expansion. Historical examples such as Zoom, Shopify, and Snowflake have been valued at multiples between 50 and 200 during peak growth phases. While Tesla reached a peak valuation multiple of 30, it has lately come down to nearly 10x. Even applying a conservative revenue multiple of 15x to QuantumScape's projected $10 billion in revenue for 2030 suggests a potential valuation of $150 billion—around 40 times current levels.
Competitive Advantages
QuantumScape's technology provides significant advantages over traditional lithium-ion batteries: quicker charging, extended range, improved safety, and greater longevity. The company's collaboration with PowerCo offers a direct pathway to mass production via Volkswagen's established automotive supply chain, thus mitigating the commercialization risks typically associated with emerging battery technologies.
The Cobra manufacturing breakthrough specifically targets the industry's two largest challenges: production scalability and cost efficiency. This technological advantage may prove hard for competitors to duplicate quickly, potentially solidifying QuantumScape's early market dominance.
Risk Considerations
Despite the compelling upside case, investors need to consider significant risks. The complexity of manufacturing remains considerable—achieving gigawatt-hour production introduces numerous technical challenges that extend beyond the Cobra process. The company is also up against fierce competition from well-capitalized adversaries such as Toyota, Samsung, and LG Chem, all of which possess established manufacturing capabilities and supply chain networks.
QuantumScape's strong reliance on the PowerCo partnership poses concentration risk, while the company's annual operating losses of $517 million and its pre-revenue status necessitate continued access to capital. Historically, the market adoption of new battery technologies tends to proceed more slowly than anticipated, which could postpone revenue generation.
Technical risks persist regarding the validation of real-world performance at scale, cost competitiveness with existing lithium-ion technologies, and the security of supply chains for the specialized materials needed for mass production.
Investment Verdict
The investment case for QuantumScape revolves around asymmetric risk-reward dynamics. While the execution risks are considerable, the company's current valuation seems to fully discount the possibility of success. The intersection of groundbreaking manufacturing technology, substantial market growth, and solid commercialization partnerships creates a highly favorable scenario that far outweighs the existing market valuation.
For investors prepared to accept the risks associated with development stages, QuantumScape offers exposure to potentially transformative battery technology at what appears to be a considerable valuation discount relative to its long-term revenue prospects. Nevertheless, it is vital for investors to thoughtfully weigh these risks as well. Now, we implement a risk assessment framework while constructing the Trefis High Quality (HQ) Portfolio, featuring a collection of 30 stocks that has a strong track record of outperforming the S&P 500 over the last four years. Why is that? Collectively, HQ Portfolio stocks have offered better returns with lower risk compared to the benchmark index; a smoother ride, as demonstrated in HQ Portfolio performance metrics.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

Yahoo

time20 minutes ago

  • Yahoo

argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative discovery model June 30, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to advance the clinical development of ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS) following the analysis of topline data from the Phase 1b study. Detailed results will be presented at a future medical meeting. 'The results of our Phase 1b ARGX-119 study in congenital myasthenic syndromes, an ultra-rare disorder that affects patients from birth, builds on our experience and understanding of myasthenic disorders and aligns with our aspiration to serve even more patients living with these debilitating diseases,' said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. 'ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept, reflecting the strength of our innovation model where our deep knowledge of the biology and expertise in antibody engineering come together to push the boundaries of what's possible. argenx remains focused on uncovering new biological insights into misunderstood diseases to meaningfully change the lives of patients who have long-been underserved,' said Peter Ulrichts, Ph.D., Chief Scientific Officer of argenx. The decision to advance the development of ARGX-119 in CMS is supported by the results of the Phase 1b study. ARGX-119 demonstrated a favorable safety and tolerability profile, which was the primary endpoint. Efficacy was evaluated across multiple secondary and exploratory endpoints, including Six-Minute Walk Test (6MWT), Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Consistent improvements were observed in treated DOK7-CMS patients through the 12-week study across multiple efficacy scores. Phase 1b CMS Study Design The Phase 1b, multicenter, randomized, double-blinded, placebo-controlled clinical trial assessed safety, tolerability, PK, immunogenicity, and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. The study was also designed to demonstrate proof-of-biology through preliminary efficacy assessments, including muscle weakness, fatigability, daily activities and patient-reported global health outcomes. The clinical trial spanned approximately 11 months across a screening period (up to 28 days), a 12-week treatment period and a follow-up period of nearly seven months. At baseline, eligible participants were randomized 4:1 to receive intravenous ARGX-119 or placebo. The primary objective was to evaluate safety and tolerability; secondary objectives included PK, immunogenicity and preliminary efficacy of ARGX-119 in participants with DOK7-CMS. All but one of the patients enrolled in the Phase 1b study also participated in an observational natural history study initiated by argenx in 2024 to better understand the CMS patient journey and disease burden, helping to inform future development plans. About Congenital Myasthenic Syndromes Congenital Myasthenic Syndromes (CMS) are an ultra-rare and heterogenous group of congenital neuromuscular disorders caused by genetic defects that are essential for the integrity of the neuromuscular junction. Early age of onset and fatigable muscle weakness are considered clinical hallmarks of CMS. Muscle weakness can be debilitating and life-threatening causing difficulties in speaking or swallowing, impaired or absent mobility, proximal arm and leg weakness, and respiratory insufficiency. DOK7 variations are one of the more frequent and severe causes of CMS, accounting for approximately 24% of CMS cases. There are no approved treatments. The prevalence of CMS is estimated to be 5 per 1M (DOK7-CMS estimated to be 1.2 per 1M). About ARGX-119 ARGX-119 is a first-in-class humanized agonist monoclonal antibody (mAb) that specifically targets and activates muscle-specific tyrosine kinase (MuSK) to promote maturation and stabilization of the neuromuscular junction (NMJ). It is a mAb derived from llamas and discovered using the argenx SIMPLE Antibody™ platform technology. ARGX-119 is being developed for patients with neuromuscular disease, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). ARGX-119 was developed through argenx's IIP program in collaboration with the world's leading key opinion leaders on MuSK and the NMJ, Professor Steven J. Burden from MGH, Professor Shohei Koide from NYU and Professor Jan Verschuuren and Associate Professor Maartje Huijbers from LUMC. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. Media: Colin McBeancmcbean@ Investors: Alexandra Roy aroy@ Forward Looking Statements The contents of this announcement include statements that are, or may be deemed to be, 'forward looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'aims,' 'committed,' or 'plan' and include statements argenx makes concerning its commitment to improving the lives of people suffering from severe autoimmune diseases; its plan to advance the clinical development of ARGX-119 to a registrational study in CMS patients; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Cannes is done with huge cruise ships. The French city is joining the overtourism backlash
Cannes is done with huge cruise ships. The French city is joining the overtourism backlash

Yahoo

time39 minutes ago

  • Yahoo

Cannes is done with huge cruise ships. The French city is joining the overtourism backlash

PARIS (AP) — The French Riviera resort of Cannes is imposing what its city council calls 'drastic regulation' on cruise ships, banning any vessels carrying more than 1,000 people from its harbor starting next year. The home of the world's premier film festival is joining a growing global backlash against overtourism, which recently saw uproar over Jeff Bezos' and Lauren Sanchez' Venice wedding this weekend, water-gun protests in Spain and a surprise strike at the Louvre Museum. 'Less numerous, less big, less polluting and more esthetic' — that's the aim of Cannes city councilors who voted Friday to introduce new limits on cruise ships in its ports starting Jan. 1. Only ships with fewer than 1,000 passengers will be allowed in the port, with a maximum of 6,000 passengers disembarking per day. Larger ships will be expected to transfer passengers to smaller boats to enter Cannes. France — which drew in some 100 million visitors last year, more than any other European country and more than the country's population — is on the front line of efforts to balance economic benefits of tourism with environmental concerns while managing ever-growing crowds. 'Cannes has become a major cruise ship destination, with real economic benefits. It's not about banning cruise ships, but about regulating, organizing, setting guidelines for their navigation,' Mayor David Lisnard said in a statement. Cruise operators have called such restrictions damaging for destinations and for passengers. Two cruise ships were scheduled to dock in Cannes on Sunday, each bigger than the upcoming 1,000-passenger limit and with a combined capacity of more than 7,000 people. Their owners did not immediately respond to requests for comment on the new restrictions. The nearby Mediterranean city of Nice announced limits on cruise ships earlier this year, as have some other European cities.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store